Skip to main content
Journal cover image

Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence?

Publication ,  Journal Article
Farra, C; Yunis, K; Mikati, M; Yazbeck, N; Majdalani, M; Awwad, J
Published in: Birth Defects Res A Clin Mol Teratol
July 2010

Goldenhar syndrome, also known as oculo-auriculo-vertebral spectrum, is a complex, heterogeneous condition characterized by abnormal prenatal development of facial structures. We present the occurrence of Goldenhar syndrome in an infant born to a woman with a history of prenatal Fluoxetine ingestion throughout her pregnancy. Because this is the first reported case associating maternal Fluoxetine intake with fetal craniofacial malformations, a potential mechanism of injury is discussed. The propositus, a male born from nonconsanguinous parents, had facial asymmetry with right microtia and mandibular hypoplasia; he also had bilateral hypoplastic macula, scoliotic deformity of the thoracic spine, and ventricular septal defect. The mother was under treatment with Fluoxetine 20 mg/day prior to conception and maintained the same dosage throughout her pregnancy. The drug is a selective serotonin re-uptake inhibitor, the most widely prescribed for the treatment of depression. The occurrence of developmental aberrations may be caused by a profound serotonin receptor suppressive state in utero leading to aberrant clinical manifestations of the first and second branchial arches. Despite the very many limitations of case reporting of teratogenic events, it remains an important source of information on which more advanced research is based.

Duke Scholars

Published In

Birth Defects Res A Clin Mol Teratol

DOI

EISSN

1542-0760

Publication Date

July 2010

Volume

88

Issue

7

Start / End Page

582 / 585

Location

United States

Related Subject Headings

  • Selective Serotonin Reuptake Inhibitors
  • Pregnancy
  • Maternal Exposure
  • Male
  • Infant, Newborn
  • Humans
  • Goldenhar Syndrome
  • Genetics & Heredity
  • Fluoxetine
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Farra, C., Yunis, K., Mikati, M., Yazbeck, N., Majdalani, M., & Awwad, J. (2010). Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence? Birth Defects Res A Clin Mol Teratol, 88(7), 582–585. https://doi.org/10.1002/bdra.20674
Farra, Chantal, Khalid Yunis, Mohammad Mikati, Nadine Yazbeck, Marianne Majdalani, and Johnny Awwad. “Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence?Birth Defects Res A Clin Mol Teratol 88, no. 7 (July 2010): 582–85. https://doi.org/10.1002/bdra.20674.
Farra C, Yunis K, Mikati M, Yazbeck N, Majdalani M, Awwad J. Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence? Birth Defects Res A Clin Mol Teratol. 2010 Jul;88(7):582–5.
Farra, Chantal, et al. “Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence?Birth Defects Res A Clin Mol Teratol, vol. 88, no. 7, July 2010, pp. 582–85. Pubmed, doi:10.1002/bdra.20674.
Farra C, Yunis K, Mikati M, Yazbeck N, Majdalani M, Awwad J. Goldenhar syndrome associated with prenatal maternal Fluoxetine ingestion: Cause or coincidence? Birth Defects Res A Clin Mol Teratol. 2010 Jul;88(7):582–585.
Journal cover image

Published In

Birth Defects Res A Clin Mol Teratol

DOI

EISSN

1542-0760

Publication Date

July 2010

Volume

88

Issue

7

Start / End Page

582 / 585

Location

United States

Related Subject Headings

  • Selective Serotonin Reuptake Inhibitors
  • Pregnancy
  • Maternal Exposure
  • Male
  • Infant, Newborn
  • Humans
  • Goldenhar Syndrome
  • Genetics & Heredity
  • Fluoxetine
  • Female